BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 25327687)

  • 1. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
    Murga JD; Moorji SM; Han AQ; Magargal WW; DiPippo VA; Olson WC
    Prostate; 2015 Feb; 75(3):242-54. PubMed ID: 25327687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
    DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
    Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
    Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
    Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
    Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
    Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
    Plouznikoff N; Artigas C; Sideris S; Martinez Chanza N; Gil T; Peltier A; Flamen P
    Ann Nucl Med; 2019 Dec; 33(12):945-954. PubMed ID: 31587172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates targeting prostate-specific membrane antigen.
    Olson WC; Israel RJ
    Front Biosci (Landmark Ed); 2014 Jan; 19(1):12-33. PubMed ID: 24389170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
    Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
    Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
    Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
    Evans MJ; Smith-Jones PM; Wongvipat J; Navarro V; Kim S; Bander NH; Larson SM; Sawyers CL
    Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9578-82. PubMed ID: 21606347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihormone treatment differentially regulates PSA secretion, PSMA expression and
    Mathy CS; Mayr T; Kürpig S; Meisenheimer M; Dolscheid-Pommerich RC; Stoffel-Wagner B; Kristiansen G; Essler M; Muders MH; Bundschuh RA
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1733-1743. PubMed ID: 33760944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
    Kranzbühler B; Salemi S; Umbricht CA; Müller C; Burger IA; Sulser T; Eberli D
    Prostate; 2018 Jul; 78(10):758-765. PubMed ID: 29633296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.
    DiPippo VA; Nguyen HM; Brown LG; Olson WC; Vessella RL; Corey E
    Prostate; 2016 Feb; 76(3):325-34. PubMed ID: 26585210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect and adverse event of enzalutamide and abiraterone in prostate cancer].
    Kosaka T; Oya M
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():308-12. PubMed ID: 25831773
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
    Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
    Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
    Petrylak DP; Vogelzang NJ; Chatta K; Fleming MT; Smith DC; Appleman LJ; Hussain A; Modiano M; Singh P; Tagawa ST; Gore I; McClay EF; Mega AE; Sartor AO; Somer B; Wadlow R; Shore ND; Olson WC; Stambler N; DiPippo VA; Israel RJ
    Prostate; 2020 Jan; 80(1):99-108. PubMed ID: 31742767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-analysis.
    Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
    J Clin Pharm Ther; 2020 Jun; 45(3):488-495. PubMed ID: 31951037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor-related micro RNAs in prostate cancer and their role in antiandrogen drug resistance.
    Rezaei S; Mahjoubin Tehran M; Sahebkar A; Jalili A; Aghaee-Bakhtiari SH
    J Cell Physiol; 2020 Apr; 235(4):3222-3234. PubMed ID: 31599460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
    Petrylak DP; Kantoff P; Vogelzang NJ; Mega A; Fleming MT; Stephenson JJ; Frank R; Shore ND; Dreicer R; McClay EF; Berry WR; Agarwal M; DiPippo VA; Rotshteyn Y; Stambler N; Olson WC; Morris SA; Israel RJ
    Prostate; 2019 May; 79(6):604-613. PubMed ID: 30663074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.